Get the Stockscreener App
117.10
1.65%
-1.97
Pre-market:
118.17
1.07
+0.91%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Merck Co Inc stock is traded at $117.10, with a volume of 7.37M.
It is down -1.65% in the last 24 hours and up +2.56% over the past month.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
See More
Previous Close:
$119.07
Open:
$119.15
24h Volume:
7.37M
Relative Volume:
0.65
Market Cap:
$289.22B
Revenue:
$64.93B
Net Income/Loss:
$18.26B
P/E Ratio:
16.10
EPS:
7.2751
Net Cash Flow:
$12.36B
1W Performance:
-2.54%
1M Performance:
+2.56%
6M Performance:
+35.66%
1Y Performance:
+50.13%
1-Day Range:
$116.75
$119.36
1-Week Range:
$114.71
$120.36
52-Week Range:
$73.31
$125.14
Merck Co Inc Stock (MRK) Company Profile
Name
Merck Co Inc
Sector
Industry
Phone
908-740-4000
Address
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK vs LLY, JNJ, ABBV, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
117.10 | 294.09B | 64.93B | 18.26B | 12.36B | 7.2751 |
LLY
Lilly Eli Co
|
919.90 | 828.17B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
230.69 | 564.05B | 96.36B | 21.04B | 19.70B | 8.6488 |
ABBV
Abbvie Inc
|
203.71 | 368.57B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
200.69 | 317.61B | 58.80B | 10.24B | 8.98B | 3.2788 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Feb-13-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-08-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-18-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-24-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Oct-13-25 | Resumed | Citigroup | Neutral |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-18-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-10-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-08-25 | Downgrade | Truist | Buy → Hold |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Dec-04-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-11-24 | Downgrade | Daiwa Securities | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Mar-11-24 | Downgrade | Societe Generale | Hold → Sell |
| Jan-04-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-27-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Oct-20-23 | Upgrade | UBS | Neutral → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Hold |
| Apr-13-23 | Upgrade | Citigroup | Neutral → Buy |
| Mar-28-23 | Downgrade | Societe Generale | Buy → Hold |
| Mar-13-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-06-23 | Initiated | Jefferies | Buy |
| Feb-22-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-04-23 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Oct-10-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-14-22 | Upgrade | Berenberg | Hold → Buy |
| Jul-06-22 | Upgrade | Daiwa Securities | Neutral → Buy |
| Jun-06-22 | Resumed | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-16-21 | Initiated | Daiwa Securities | Neutral |
| Dec-13-21 | Downgrade | UBS | Buy → Neutral |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Dec-07-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-29-21 | Downgrade | Citigroup | Buy → Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-01-21 | Upgrade | Argus | Hold → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-27-21 | Resumed | Truist | Buy |
| May-20-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Aug-03-20 | Upgrade | Goldman | Neutral → Buy |
| Jun-12-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-16-19 | Initiated | SVB Leerink | Outperform |
| Jul-03-19 | Initiated | Mizuho | Buy |
| May-28-19 | Initiated | Goldman | Neutral |
| May-13-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-16-18 | Reiterated | Citigroup | Buy |
| Oct-09-18 | Resumed | Guggenheim | Buy |
| Apr-23-18 | Upgrade | Goldman | Neutral → Buy |
| Apr-17-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-05-18 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-12-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Feb-14-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-07-18 | Reiterated | Morgan Stanley | Equal-Weight |
| Jan-16-18 | Upgrade | SunTrust | Hold → Buy |
View All
Merck Co Inc Stock (MRK) Latest News
Lobbying Update: $4,150,000 of MERCK & CO INC lobbying was just disclosed - Quiver Quantitative
Merck & Co., Inc. stock (US58933Y1055): Is Keytruda's dominance strong enough to unlock sustained up - AD HOC NEWS
Merck & Co. Inc. stock underperforms Monday when compared to competitors - MarketWatch
Merck & Co., Inc. stock (US58933Y1055): Is Keytruda's dominance strong enough to sustain growth? - AD HOC NEWS
Pheochromocytoma and Paraganglioma Market to Exhibit Growth at 7.3% CAGR by 2036 Driven by the Advent of Drug Classes Such as SSTR2 analogs, Dopamine Receptor D2 Agonists, TAAs or TSAs, and Others | DelveInsight - GlobeNewswire Inc.
Merck & Co., Inc. $MRK Shares Sold by Zurcher Kantonalbank Zurich Cantonalbank - MarketBeat
TD Waterhouse Canada Inc. Grows Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. stock (US58933Y1055): Is Keytruda's dominance strong enough for sustained growth? - AD HOC NEWS
Merck & Co., Inc. stock (US58933Y1055): Is Keytruda's patent cliff the real test ahead? - AD HOC NEWS
Tokio Marine Asset Management Co. Ltd. Reduces Stake in Merck & Co., Inc. $MRK - MarketBeat
Wealth Enhancement Trust Services Inc. Buys New Position in Merck & Co., Inc. $MRK - MarketBeat
Ninety One UK Ltd Sells 14,696 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. stock (US58933Y1055): Is Keytruda's dominance strong enough to sustain growth amid - AD HOC NEWS
Lobbying Update: $50,000 of MERCK & CO. INC lobbying was just disclosed - Quiver Quantitative
MASTERINVEST Kapitalanlage GmbH Increases Stake in Merck & Co., Inc. $MRK - MarketBeat
Moran Wealth Management LLC Acquires 22,157 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. stock (US58933Y1055): Is Keytruda's dominance strong enough to unlock new upside? - AD HOC NEWS
AE Wealth Management LLC Sells 102,481 Shares of Merck & Co., Inc. $MRK - MarketBeat
Asset Management One Co. Ltd. Grows Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
A Look at Merck & Co Inc (MRK) After 3.1% Gain -- GF Value $117. - GuruFocus
Merck & Co Inc (MRK) Stock Price, Trades & News - GuruFocus
Merck & Co. Inc. stock outperforms competitors on strong trading day - MarketWatch
Merck & Co Inc Stock (MRK) Closed Up by 3.07% on Apr 17: What Signal Does It Send? - TradingKey
Merck & Co. Inc. stock (US58933Y1055): Is Keytruda's patent cliff the real test ahead? - AD HOC NEWS
UBS Raises Merck (MRK) Price Forecast as Part of Sector Preview - Insider Monkey
Whittier Trust Co. Increases Stake in Merck & Co., Inc. $MRK - MarketBeat
Whittier Trust Co. of Nevada Inc. Sells 11,310 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co. prepares and tests new IL4I1 inhibitors - BioWorld News
Leerink raises Merck & Co. Inc. (MRK) price target, sees upside from cancer drug - MSN
Roof Eidam Maycock Peralta LLC Purchases New Stake in Merck & Co., Inc. $MRK - MarketBeat
Merit Financial Group LLC Increases Position in Merck & Co., Inc. $MRK - MarketBeat
Europe approves Merck RSV preventive for newborns in first season - Stock Titan
Mirae Asset Global Investments Co. Ltd. Sells 178,997 Shares of Merck & Co., Inc. $MRK - MarketBeat
Meropenem Market Is Booming So Rapidly | Merck & Co. • Pfizer Inc. • AstraZeneca - openPR.com
Greenwood Capital Associates LLC Invests $1.09 Million in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co. Inc. stock underperforms Thursday when compared to competitors - MarketWatch
FDA grants priority review to Merck-Daiichi’s B7-H3 cancer ADC - BioWorld News
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
KBC Group NV Increases Stock Position in Merck & Co., Inc. $MRK - MarketBeat
Lbp Am Sa Has $39.73 Million Position in Merck & Co., Inc. $MRK - MarketBeat
Diversified Management Inc. Invests $909,000 in Merck & Co., Inc. $MRK - MarketBeat
Cwm LLC Buys 61,957 Shares of Merck & Co., Inc. $MRK - MarketBeat
Childress Capital Advisors LLC Increases Stake in Merck & Co., Inc. $MRK - MarketBeat
Farther Finance Advisors LLC Raises Holdings in Merck & Co., Inc. $MRK - MarketBeat
Adelphi Trust Co Acquires Shares of 10,969 Merck & Co., Inc. $MRK - MarketBeat
Merck & Co. Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
BCS Wealth Management Boosts Position in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co. Inc. stock (US58933Y1055): Is its oncology dominance strong enough to unlock new upside? - AD HOC NEWS
Is Merck & Co. (NYSE:MRK) Driving Growth In The Russell 1000 Index? - Kalkine Media
HARTFORD CAPITAL APPRECIATION HLS FUND's Merck & Co Inc(MRK) Holding History - GuruFocus
Merck & Co. Inc. stock (US58933Y1055): Is Keytruda's dominance strong enough to unlock new upside? - AD HOC NEWS
Merck Co Inc Stock (MRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):